Validation of HDAC6 and SIRT2 tubulin deacetylases as therapeutic targets for Huntington's disease
Since the identification of a widespread transcriptional dysregulation that occurs in Huntington's disease (HD), histone deacetylase (HDAC) inhibition has been explored as a possible therapeutic strategy for this devastating disease. Studies using broadrange acting HDAC inhibitors have shown gr...
Main Author: | |
---|---|
Published: |
King's College London (University of London)
2012
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628114 |